176 related articles for article (PubMed ID: 19543543)
21. Salivary protein/peptide profiling with SELDI-TOF-MS.
Schipper R; Loof A; de Groot J; Harthoorn L; van Heerde W; Dransfield E
Ann N Y Acad Sci; 2007 Mar; 1098():498-503. PubMed ID: 17435159
[TBL] [Abstract][Full Text] [Related]
22. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices.
Poon TC
Expert Rev Proteomics; 2007 Feb; 4(1):51-65. PubMed ID: 17288515
[TBL] [Abstract][Full Text] [Related]
23. Saliva analysis by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF/MS): from sample collection to data analysis.
Papale M; Pedicillo MC; Di Paolo S; Thatcher BJ; Lo Muzio L; Bufo P; Rocchetti MT; Centra M; Ranieri E; Gesualdo L
Clin Chem Lab Med; 2008; 46(1):89-99. PubMed ID: 18020972
[TBL] [Abstract][Full Text] [Related]
24. Differences in protein profiles of the isolates of Entamoeba histolytica and E. dispar by surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS) ProteinChip assays.
Makioka A; Kumagai M; Kobayashi S; Takeuchi T
Parasitol Res; 2007 Dec; 102(1):103-10. PubMed ID: 17846790
[TBL] [Abstract][Full Text] [Related]
25. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery.
Seibert V; Ebert MP; Buschmann T
Brief Funct Genomic Proteomic; 2005 May; 4(1):16-26. PubMed ID: 15975261
[TBL] [Abstract][Full Text] [Related]
26. MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers.
Cazares LH; Diaz JI; Drake RR; Semmes OJ
Methods Mol Biol; 2008; 428():125-40. PubMed ID: 18287771
[TBL] [Abstract][Full Text] [Related]
27. Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis.
Novikova SI; He F; Cutrufello NJ; Lidow MS
Neurobiol Dis; 2006 Jul; 23(1):61-76. PubMed ID: 16549361
[TBL] [Abstract][Full Text] [Related]
28. The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers.
Soltys SG; Le QT; Shi G; Tibshirani R; Giaccia AJ; Koong AC
Clin Cancer Res; 2004 Jul; 10(14):4806-12. PubMed ID: 15269156
[TBL] [Abstract][Full Text] [Related]
29. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
30. Using SELDI-TOF mass spectrometry on amniotic fluid and for clinical proteomics and theranostics in disorders of pregnancy.
Buhimschi IA
Methods Mol Biol; 2012; 818():171-97. PubMed ID: 22083824
[TBL] [Abstract][Full Text] [Related]
31. Proteomic studies in breast cancer (Review).
Qin XJ; Ling BX
Oncol Lett; 2012 Apr; 3(4):735-743. PubMed ID: 22740985
[TBL] [Abstract][Full Text] [Related]
32. [Research progress in SELDI-TOF MS and its clinical applications].
Cho WC
Sheng Wu Gong Cheng Xue Bao; 2006 Nov; 22(6):871-6. PubMed ID: 17168305
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
[TBL] [Abstract][Full Text] [Related]
34. Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis.
Cadieux PA; Beiko DT; Watterson JD; Burton JP; Howard JC; Knudsen BE; Gan BS; McCormick JK; Chambers AF; Denstedt JD; Reid G
J Clin Lab Anal; 2004; 18(3):170-5. PubMed ID: 15103681
[TBL] [Abstract][Full Text] [Related]
35. Interest of major serum protein removal for Surface-Enhanced Laser Desorption/Ionization - Time Of Flight (SELDI-TOF) proteomic blood profiling.
Roche S; Tiers L; Provansal M; Piva MT; Lehmann S
Proteome Sci; 2006 Oct; 4():20. PubMed ID: 17022823
[TBL] [Abstract][Full Text] [Related]
36. SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics.
Simpkins F; Czechowicz JA; Liotta L; Kohn EC
Pharmacogenomics; 2005 Sep; 6(6):647-53. PubMed ID: 16143004
[TBL] [Abstract][Full Text] [Related]
37. Proteomic profiling of growth hormone-responsive proteins in human peripheral blood leukocytes.
Chung L; Nelson AE; Ho KK; Baxter RC
J Clin Endocrinol Metab; 2009 Aug; 94(8):3038-43. PubMed ID: 19491220
[TBL] [Abstract][Full Text] [Related]
38. Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics.
Bouamrani A; Ternier J; Ratel D; Benabid AL; Issartel JP; Brambilla E; Berger F
Clin Chem; 2006 Nov; 52(11):2103-6. PubMed ID: 16990423
[TBL] [Abstract][Full Text] [Related]
39. [Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers].
Solassol J; Marin P; Maudelonde T; Mangé A
Bull Cancer; 2005 Sep; 92(9):763-8. PubMed ID: 16203265
[TBL] [Abstract][Full Text] [Related]
40. Salivary Proteomic Analysis of Canine Oral Melanoma by MALDI-TOF Mass Spectrometry and LC-Mass Spectrometry/Mass Spectrometry.
Ploypetch S; Roytrakul S; Suriyaphol G
Methods Mol Biol; 2021; 2265():429-445. PubMed ID: 33704732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
